Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial

被引：17
|
作者：
Katsiki, Niki [1 ]
Athyros, Vasilios G. [1 ]
Mikhailidis, Dimitri P. [2 ]
Mantzoros, Christos [3 ]
机构：
[1] Aristotle Univ Thessaloniki, Hippocrat Hosp, Med Sch, Propedeut Dept Internal Med 2, Thessaloniki, Greece
[2] UCL, Royal Free Hosp Campus, Med Sch, Dept Clin Biochem, London, England
[3] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Internal Med, Div Endocrinol Diabet & Metab, Boston, MA USA
来源：
METABOLISM-CLINICAL AND EXPERIMENTAL | 2017年 / 74卷
关键词：
GENETIC-VARIANTS; REDUCING LIPIDS; STATIN THERAPY; MANAGEMENT; EVOLOCUMAB; EFFICACY; SAFETY; DYSLIPIDEMIA; ASSOCIATION; ALIROCUMAB;
D O I：
10.1016/j.metabol.2017.04.007
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：43 / 46
页数：4
相关论文
共 50 条
  • [1] Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors
    Leong, Derek
    Wu, Peter E.
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2019, 191 (32) : E894 - E894
  • [2] Proprotein convertase subtilisin/kexin type 9 (PCSK9) and inhibitors
    Avci, Ahmet
    Demir, Kenan
    Altunkeser, Bulent Behlul
    TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, 2014, 42 : 56 - 67
  • [3] The impact of discontinuing proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors on clinical outcomes
    Tsubata, H.
    Wakana, N.
    Yanishi, K.
    Nakanishi, N.
    Zen, K.
    Nakamura, T.
    Matoba, S.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [4] The impact of discontinuing proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors on clinical outcomes
    Tsubata, H.
    Wakana, N.
    Yanishi, K.
    Nakanishi, N.
    Zen, K.
    Nakamura, T.
    Matoba, S.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [5] PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future
    Shimada, Yuichi J.
    Cannon, Christopher P.
    EUROPEAN HEART JOURNAL, 2015, 36 (36) : 2415 - U36
  • [6] Treatment with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors to Reduce Cardiovascular Inflammation and Outcomes
    Liberale, Luca
    Montecucco, Fabrizio
    Camici, Giovanni G.
    Dallegri, Franco
    Vecchie, Alessandra
    Carbone, Federico
    Bonaventura, Aldo
    CURRENT MEDICINAL CHEMISTRY, 2017, 24 (14) : 1403 - 1416
  • [7] Hyperlipidemia: Management with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors
    Shahreyar, Muhammed
    Salem, Salem A.
    Nayyar, Mannu
    George, Lekha K.
    Garg, Nadish
    Koshy, Santhosh K. G.
    JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE, 2018, 31 (04) : 628 - 634
  • [8] Pleiotropic Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors?
    Bittner, Vera
    CIRCULATION, 2016, 134 (22) : 1695 - 1696
  • [9] PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibition and Stroke Prevention Another Step Forward
    Alberts, Mark J.
    Thompson, Paul D.
    STROKE, 2020, 51 (05) : 1361 - 1362
  • [10] PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9): A Narrative Review
    Dua, Pamila
    Reeta, K. H.
    JOURNAL OF THE PRACTICE OF CARDIOVASCULAR SCIENCES, 2020, 6 (03) : 226 - 233
12345